C Krishna Prasad, MD, Granules India , spoke to CNBC-TV 18 about the company's performance and what to expect in the days to come.
Below is a verbatim transcript. Also watch the accompanying video
Q: You have seen about a 45% growth in your net sales and an equivalent smart improvement in your operating profits as well. Is this growth run-rate likely to continue? A: Yes, it is likely to continue and improve as we go by quarter-on-quarter.
Q: So what would FY12 and FY13 look like? A: This year we will be having a growth rate of about 40% and next year we will be close to that.
Q: In terms of key growth drivers, geographically and segment wise, where is this majority growth coming for you? A: Geography wise it is mainly Europe, followed by the US and segment wise its PFIs and Finished Dosages together. Both have an equally impressive growth rate.
Q: What about the Indian markets? Do you operate in the Indian markets at all and what would be your trajectory there?
A: We do operate in Indian market. It's very low volume. We sell only APIs. PFIs and FDs are only for the export markets. Sales in the domestic markets are falling. This year they will be 9%. We are short of capacity today but as we increase capacities, we will be concentrating on the domestic market too.
Q: This JV that you have signed with Ajinomoto OmniChem, is it quite significant and will it contribute to your revenues in FY13 or will it come in later? A: It will be in FY14-FY15. in Fiscal Year 13 they will commence operation, but the real effect will come in FY14-FY15.
